ID   AKT1_HUMAN              Reviewed;         480 AA.
AC   P31749; Q9BWB6;
DT   01-JUL-1993, integrated into UniProtKB/Swiss-Prot.
DT   01-FEB-2005, sequence version 2.
DT   05-OCT-2010, entry version 139.
DE   RecName: Full=RAC-alpha serine/threonine-protein kinase;
DE            EC=2.7.11.1;
DE   AltName: Full=Protein kinase B;
DE            Short=PKB;
DE   AltName: Full=Proto-oncogene c-Akt;
DE   AltName: Full=RAC-PK-alpha;
GN   Name=AKT1; Synonyms=PKB, RAC;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND CATALYTIC ACTIVITY.
RX   MEDLINE=91239529; PubMed=1851997; DOI=10.1073/pnas.88.10.4171;
RA   Jones P.F., Jakubowicz T., Pitossi F.J., Maurer F., Hemmings B.A.;
RT   "Molecular cloning and identification of a serine/threonine protein
RT   kinase of the second-messenger subfamily.";
RL   Proc. Natl. Acad. Sci. U.S.A. 88:4171-4175(1991).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   MEDLINE=21399046; PubMed=11508278; DOI=10.1007/s001250100577;
RA   Matsubara A., Wasson J.C., Donelan S.S., Welling C.M., Glaser B.,
RA   Permutt M.A.;
RT   "Isolation and characterization of the human AKT1 gene, identification
RT   of 13 single nucleotide polymorphisms (SNPs), and their lack of
RT   association with Type II diabetes.";
RL   Diabetologia 44:910-913(2001).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Muscle, and Ovary;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 63-480, FUNCTION, CATALYTIC ACTIVITY,
RP   AND TISSUE SPECIFICITY.
RC   TISSUE=Foreskin;
RX   MEDLINE=92037600; PubMed=1718748;
RX   DOI=10.1111/j.1432-1033.1991.tb16305.x;
RA   Coffer P.J., Woodgett J.R.;
RT   "Molecular cloning and characterisation of a novel putative protein-
RT   serine kinase related to the cAMP-dependent and protein kinase C
RT   families.";
RL   Eur. J. Biochem. 201:475-481(1991).
RN   [5]
RP   ERRATUM, AND SEQUENCE REVISION.
RX   MEDLINE=92249329; PubMed=1533586;
RA   Coffer P.J., Woodgett J.R.;
RL   Eur. J. Biochem. 205:1217-1218(1992).
RN   [6]
RP   ENZYME REGULATION, AND PHOSPHORYLATION AT SER-473.
RX   MEDLINE=98409636; PubMed=9736715; DOI=10.1073/pnas.95.19.11211;
RA   Delcommenne M., Tan C., Gray V., Rue L., Woodgett J.R., Dedhar S.;
RT   "Phosphoinositide-3-OH kinase-dependent regulation of glycogen
RT   synthase kinase 3 and protein kinase B/AKT by the integrin-linked
RT   kinase.";
RL   Proc. Natl. Acad. Sci. U.S.A. 95:11211-11216(1998).
RN   [7]
RP   MUTAGENESIS OF THR-308 AND SER-473, AND PHOSPHORYLATION AT THR-308 AND
RP   SER-473.
RX   MEDLINE=97133284; PubMed=8978681;
RA   Alessi D.R., Andjelkovic M., Caudwell F.B., Cron P., Morrice N.,
RA   Cohen P., Hemmings B.A.;
RT   "Mechanism of activation of protein kinase B by insulin and IGF-1.";
RL   EMBO J. 15:6541-6551(1996).
RN   [8]
RP   FUNCTION, ENZYME REGULATION, AND PHOSPHORYLATION AT THR-308 BY PDPK1.
RX   PubMed=9512493;
RA   Walker K.S., Deak M., Paterson A., Hudson K., Cohen P., Alessi D.R.;
RT   "Activation of protein kinase B beta and gamma isoforms by insulin in
RT   vivo and by 3-phosphoinositide-dependent protein kinase-1 in vitro:
RT   comparison with protein kinase B alpha.";
RL   Biochem. J. 331:299-308(1998).
RN   [9]
RP   INTERACTION WITH MTCP1; TCL1A AND TCL1B.
RX   PubMed=10983986; DOI=10.1016/S1097-2765(00)00039-3;
RA   Laine J., Kuenstle G., Obata T., Sha M., Noguchi M.;
RT   "The protooncogene TCL1 is an Akt kinase coactivator.";
RL   Mol. Cell 6:395-407(2000).
RN   [10]
RP   INTERACTION WITH TCL1A.
RX   PubMed=10716693; DOI=10.1073/pnas.040557697;
RA   Pekarsky Y., Koval A., Hallas C., Bichi R., Tresini M., Malstrom S.,
RA   Russo G., Tsichlis P., Croce C.M.;
RT   "Tcl1 enhances Akt kinase activity and mediates its nuclear
RT   translocation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 97:3028-3033(2000).
RN   [11]
RP   INTERACTION WITH THEM4, AND SUBCELLULAR LOCATION.
RX   PubMed=11598301; DOI=10.1126/science.1062030;
RA   Maira S.-M., Galetic I., Brazil D.P., Kaech S., Ingley E., Thelen M.,
RA   Hemmings B.A.;
RT   "Carboxyl-terminal modulator protein (CTMP), a negative regulator of
RT   PKB/Akt and v-Akt at the plasma membrane.";
RL   Science 294:374-380(2001).
RN   [12]
RP   FUNCTION IN PHOSPHORYLATION OF TBC1D4.
RX   MEDLINE=22063368; PubMed=11994271; DOI=10.1074/jbc.C200198200;
RA   Kane S., Sano H., Liu S.C.H., Asara J.M., Lane W.S., Garner C.C.,
RA   Lienhard G.E.;
RT   "A method to identify serine kinase substrates. Akt phosphorylates a
RT   novel adipocyte protein with a Rab GTPase-activating protein (GAP)
RT   domain.";
RL   J. Biol. Chem. 277:22115-22118(2002).
RN   [13]
RP   INTERACTION WITH CDKN1B, AND FUNCTION.
RX   PubMed=12042314; DOI=10.1074/jbc.M203668200;
RA   Fujita N., Sato S., Katayama K., Tsuruo T.;
RT   "Akt-dependent phosphorylation of p27Kip1 promotes binding to 14-3-3
RT   and cytoplasmic localization.";
RL   J. Biol. Chem. 277:28706-28713(2002).
RN   [14]
RP   PHOSPHORYLATION AT TYR-474, AND MUTAGENESIS OF TYR-474.
RX   MEDLINE=22254844; PubMed=12149249; DOI=10.1074/jbc.M203387200;
RA   Conus N.M., Hannan K.M., Cristiano B.E., Hemmings B.A., Pearson R.B.;
RT   "Direct identification of tyrosine 474 as a regulatory phosphorylation
RT   site for the Akt protein kinase.";
RL   J. Biol. Chem. 277:38021-38028(2002).
RN   [15]
RP   FUNCTION IN PHOSPHORYLATION OF TSC2.
RX   PubMed=12150915; DOI=10.1016/S1097-2765(02)00568-3;
RA   Manning B.D., Tee A.R., Logsdon M.N., Blenis J., Cantley L.C.;
RT   "Identification of the tuberous sclerosis complex-2 tumor suppressor
RT   gene product tuberin as a target of the phosphoinositide 3-kinase/akt
RT   pathway.";
RL   Mol. Cell 10:151-162(2002).
RN   [16]
RP   INTERACTION WITH TCL1A.
RX   PubMed=11839817; DOI=10.1128/MCB.22.5.1513-1525.2002;
RA   Kuenstle G., Laine J., Pierron G., Kagami S., Nakajima H., Hoh F.,
RA   Roumestand C., Stern M.H., Noguchi M.;
RT   "Identification of Akt association and oligomerization domains of the
RT   Akt kinase coactivator TCL1.";
RL   Mol. Cell. Biol. 22:1513-1525(2002).
RN   [17]
RP   INTERACTION WITH CDKN1B, FUNCTION, AND MUTAGENESIS OF THR-308 AND
RP   SER-473.
RX   PubMed=12244301; DOI=10.1038/nm759;
RA   Shin I., Yakes F.M., Rojo F., Shin N.-Y., Bakin A.V., Baselga J.,
RA   Arteaga C.L.;
RT   "PKB/Akt mediates cell-cycle progression by phosphorylation of
RT   p27(Kip1) at threonine 157 and modulation of its cellular
RT   localization.";
RL   Nat. Med. 8:1145-1152(2002).
RN   [18]
RP   INTERACTION WITH AGAP2, AND PHOSPHORYLATION AT SER-473.
RX   PubMed=14761976; DOI=10.1074/jbc.M312175200;
RA   Ahn J.-Y., Rong R., Kroll T.G., Van Meir E.G., Snyder S.H., Ye K.;
RT   "PIKE (phosphatidylinositol 3-kinase enhancer)-A GTPase stimulates Akt
RT   activity and mediates cellular invasion.";
RL   J. Biol. Chem. 279:16441-16451(2004).
RN   [19]
RP   PHOSPHORYLATION AT SER-473.
RX   PubMed=15047712; DOI=10.1074/jbc.M314192200;
RA   Kunapuli P., Kasyapa C.S., Hawthorn L., Cowell J.K.;
RT   "LGI1, a putative tumor metastasis suppressor gene, controls in vitro
RT   invasiveness and expression of matrix metalloproteinases in glioma
RT   cells through the ERK1/2 pathway.";
RL   J. Biol. Chem. 279:23151-23157(2004).
RN   [20]
RP   ERRATUM.
RA   Kunapuli P., Kasyapa C.S., Hawthorn L., Cowell J.K.;
RL   J. Biol. Chem. 282:2752-2752(2007).
RN   [21]
RP   INTERACTION WITH AKTIP.
RX   PubMed=14749367; DOI=10.1128/MCB.24.4.1493-1504.2004;
RA   Remy I., Michnick S.W.;
RT   "Regulation of apoptosis by the Ft1 protein, a new modulator of
RT   protein kinase B/Akt.";
RL   Mol. Cell. Biol. 24:1493-1504(2004).
RN   [22]
RP   INTERACTION WITH AGAP2.
RX   PubMed=15118108; DOI=10.1073/pnas.0400921101;
RA   Ahn J.-Y., Hu Y., Kroll T.G., Allard P., Ye K.;
RT   "PIKE-A is amplified in human cancers and prevents apoptosis by up-
RT   regulating Akt.";
RL   Proc. Natl. Acad. Sci. U.S.A. 101:6993-6998(2004).
RN   [23]
RP   FUNCTION, CATALYTIC ACTIVITY, AND INTERACTION WITH CCDC88A.
RX   PubMed=16139227; DOI=10.1016/j.devcel.2005.08.001;
RA   Enomoto A., Murakami H., Asai N., Morone N., Watanabe T., Kawai K.,
RA   Murakumo Y., Usukura J., Kaibuchi K., Takahashi M.;
RT   "Akt/PKB regulates actin organization and cell motility via
RT   Girdin/APE.";
RL   Dev. Cell 9:389-402(2005).
RN   [24]
RP   PHOSPHORYLATION AT THR-308 AND SER-473.
RX   PubMed=15718470; DOI=10.1126/science.1106148;
RA   Sarbassov D.D., Guertin D.A., Ali S.M., Sabatini D.M.;
RT   "Phosphorylation and regulation of Akt/PKB by the rictor-mTOR
RT   complex.";
RL   Science 307:1098-1101(2005).
RN   [25]
RP   PHOSPHORYLATION AT SER-473.
RX   PubMed=17013611; DOI=10.1007/s00401-006-0128-y;
RA   Schick V., Majores M., Engels G., Spitoni S., Koch A., Elger C.E.,
RA   Simon M., Knobbe C., Bluemcke I., Becker A.J.;
RT   "Activation of Akt independent of PTEN and CTMP tumor-suppressor gene
RT   mutations in epilepsy-associated Taylor-type focal cortical
RT   dysplasias.";
RL   Acta Neuropathol. 112:715-725(2006).
RN   [26]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-124; SER-126 AND
RP   SER-129, AND MASS SPECTROMETRY.
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P.,
RA   Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in
RT   signaling networks.";
RL   Cell 127:635-648(2006).
RN   [27]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-124; SER-126 AND
RP   SER-129, AND MASS SPECTROMETRY.
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [28]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RA   Colinge J., Superti-Furga G., Bennett K.L.;
RL   Submitted (OCT-2008) to UniProtKB.
RN   [29]
RP   UBIQUITINATION BY TTC3.
RX   PubMed=20059950; DOI=10.1016/j.devcel.2009.09.007;
RA   Suizu F., Hiramuki Y., Okumura F., Matsuda M., Okumura A.J.,
RA   Hirata N., Narita M., Kohno T., Yokota J., Bohgaki M., Obuse C.,
RA   Hatakeyama S., Obata T., Noguchi M.;
RT   "The E3 ligase TTC3 facilitates ubiquitination and degradation of
RT   phosphorylated Akt.";
RL   Dev. Cell 17:800-810(2009).
RN   [30]
RP   UBIQUITINATION, INTERACTION WITH TRAF6, AND MUTAGENESIS OF LYS-8;
RP   LYS-14 AND GLU-17.
RX   PubMed=19713527; DOI=10.1126/science.1175065;
RA   Yang W.-L., Wang J., Chan C.-H., Lee S.-W., Campos A.D., Lamothe B.,
RA   Hur L., Grabiner B.C., Lin X., Darnay B.G., Lin H.-K.;
RT   "The E3 ligase TRAF6 regulates Akt ubiquitination and activation.";
RL   Science 325:1134-1138(2009).
RN   [31]
RP   VARIANT BREAST CANCER LYS-17, AND CHARACTERIZATION OF VARIANT BREAST
RP   CANCER LYS-17.
RX   PubMed=17611497; DOI=10.1038/nature05933;
RA   Carpten J.D., Faber A.L., Horn C., Donoho G.P., Briggs S.L.,
RA   Robbins C.M., Hostetter G., Boguslawski S., Moses T.Y., Savage S.,
RA   Uhlik M., Lin A., Du J., Qian Y.-W., Zeckner D.J., Tucker-Kellogg G.,
RA   Touchman J., Patel K., Mousses S., Bittner M., Schevitz R.,
RA   Lai M.-H.T., Blanchard K.L., Thomas J.E.;
RT   "A transforming mutation in the pleckstrin homology domain of AKT1 in
RT   cancer.";
RL   Nature 448:439-444(2007).
CC   -!- FUNCTION: Plays a role as a key modulator of the AKT-mTOR
CC       signaling pathway controlling the tempo of the process of newborn
CC       neurons integration during adult neurogenesis, including correct
CC       neuron positioning, dendritic development and synapse formation
CC       (By similarity). General protein kinase capable of phosphorylating
CC       several known proteins. Phosphorylates TBC1D4. Signals downstream
CC       of phosphatidylinositol 3-kinase (PI(3)K) to mediate the effects
CC       of various growth factors such as platelet-derived growth factor
CC       (PDGF), epidermal growth factor (EGF), insulin and insulin-like
CC       growth factor I (IGF-I). Plays a role in glucose transport by
CC       mediating insulin-induced translocation of the GLUT4 glucose
CC       transporter to the cell surface. Mediates the antiapoptotic
CC       effects of IGF-I. Mediates insulin-stimulated protein synthesis by
CC       phosphorylating TSC2 at 'Ser-939' and 'Thr-1462', thereby
CC       activating mTORC1 signaling and leading to both phosphorylation of
CC       4E-BP1 and in activation of RPS6KB1. Promotes glycogen synthesis
CC       by mediating the insulin-induced activation of glycogen synthase.
CC   -!- CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.
CC   -!- ENZYME REGULATION: Three specific sites, one in the kinase domain
CC       (Thr-308) and the two other ones in the C-terminal regulatory
CC       region (Ser-473 and Tyr-474), need to be phosphorylated for its
CC       full activation.
CC   -!- SUBUNIT: Interacts with AGAP2 isoform 2 (PIKE-A) in the presence
CC       of guanine nucleotides. The C-terminus interacts with CCDC88A/GRDN
CC       and THEM4. Interacts with AKTIP. Interacts (via PH domain) with
CC       MTCP1, TCL1A AND TCL1B. Interacts with CDKN1B; the interaction
CC       phosphorylates CDKN1B promoting 14-3-3 binding and cell-cycle
CC       progression. Interacts with TRAF6. Interacts with GRB10; the
CC       interaction leads to GRB10 phosphorylation thus promoting
CC       YWHAE/14-3-3-binding (By similarity).
CC   -!- INTERACTION:
CC       Self; NbExp=1; IntAct=EBI-296087, EBI-296087;
CC       P29067:Arrb2 (xeno); NbExp=2; IntAct=EBI-296087, EBI-1636616;
CC       Q8IXJ9:ASXL1; NbExp=1; IntAct=EBI-296087, EBI-1646500;
CC       O95999:BCL10; NbExp=3; IntAct=EBI-296087, EBI-958922;
CC       O43521:BCL2L11; NbExp=1; IntAct=EBI-296087, EBI-526406;
CC       Q16543:CDC37; NbExp=1; IntAct=EBI-296087, EBI-295634;
CC       P49841:GSK3B; NbExp=1; IntAct=EBI-296087, EBI-373586;
CC       Q99683:MAP3K5; NbExp=2; IntAct=EBI-296087, EBI-476263;
CC       O60437:PPL; NbExp=1; IntAct=EBI-296087, EBI-368321;
CC       Q9NUC0:SERTAD4; NbExp=1; IntAct=EBI-296087, EBI-1773811;
CC       Q15047:SETDB1; NbExp=6; IntAct=EBI-296087, EBI-79691;
CC       Q7Z6J0:SH3RF1; NbExp=1; IntAct=EBI-296087, EBI-311339;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm. Nucleus. Cell membrane.
CC       Note=Nucleus after activation by integrin-linked protein kinase 1
CC       (ILK1). Nuclear translocation is enhanced by interaction with
CC       TCL1A.
CC   -!- TISSUE SPECIFICITY: Expressed in all human cell types so far
CC       analyzed.
CC   -!- DOMAIN: Binding of the PH domain to the phosphatidylinositol 3-
CC       kinase alpha (PI(3)K) results in its targeting to the plasma
CC       membrane.
CC   -!- DOMAIN: The AGC-kinase C-terminal mediates interaction with THEM4.
CC   -!- PTM: Phosphorylation on Thr-308, Ser-473 and Tyr-474 is required
CC       for full activity. Ser-473 phosphorylation by mTORC2 favors Thr-
CC       308 phosphorylation by PDPK1. Ser-473 phosphorylation is enhanced
CC       by interaction with AGAP2 isoform 2 (PIKE-A). Ser-473
CC       phosphorylation is enhanced in focal cortical dysplasias with
CC       Taylor-type balloon cells.
CC   -!- PTM: Ubiquitinated; undergoes both 'Lys-48'- and 'Lys-63'-linked
CC       polyubiquitination. TRAF6-induced 'Lys-63'-linked AKT1
CC       ubiquitination is critical for phosphorylation and activation.
CC       When ubiquitinated, it translocates to the plasma membrane, where
CC       it becomes phosphorylated. When fully phosphorylated and
CC       translocated into the nucleus, undergoes 'Lys-48'-
CC       polyubiquitination catalyzed by TTC3, leading to its degradation
CC       by the proteasome.
CC   -!- DISEASE: Defects in AKT1 are a cause of susceptibility to breast
CC       cancer (BC) [MIM:114480]. A common malignancy originating from
CC       breast epithelial tissue. Breast neoplasms can be distinguished by
CC       their histologic pattern. Invasive ductal carcinoma is by far the
CC       most common type. Breast cancer is etiologically and genetically
CC       heterogeneous. Important genetic factors have been indicated by
CC       familial occurrence and bilateral involvement. Mutations at more
CC       than one locus can be involved in different families or even in
CC       the same case.
CC   -!- DISEASE: Defects in AKT1 are associated with colorectal cancer
CC       (CRC) [MIM:114500].
CC   -!- DISEASE: Defects in AKT1 are associated with susceptibility to
CC       ovarian cancer [MIM:604370]; also called susceptibility to
CC       familial breast-ovarian cancer type 1 (BROVCA1).
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. AGC Ser/Thr
CC       protein kinase family. RAC subfamily.
CC   -!- SIMILARITY: Contains 1 AGC-kinase C-terminal domain.
CC   -!- SIMILARITY: Contains 1 PH domain.
CC   -!- SIMILARITY: Contains 1 protein kinase domain.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M63167; AAA36539.1; -; mRNA.
DR   EMBL; AF283830; AAL55732.1; -; Genomic_DNA.
DR   EMBL; AF283819; AAL55732.1; JOINED; Genomic_DNA.
DR   EMBL; AF283820; AAL55732.1; JOINED; Genomic_DNA.
DR   EMBL; AF283821; AAL55732.1; JOINED; Genomic_DNA.
DR   EMBL; AF283822; AAL55732.1; JOINED; Genomic_DNA.
DR   EMBL; AF283823; AAL55732.1; JOINED; Genomic_DNA.
DR   EMBL; AF283824; AAL55732.1; JOINED; Genomic_DNA.
DR   EMBL; AF283825; AAL55732.1; JOINED; Genomic_DNA.
DR   EMBL; AF283826; AAL55732.1; JOINED; Genomic_DNA.
DR   EMBL; AF283827; AAL55732.1; JOINED; Genomic_DNA.
DR   EMBL; AF283828; AAL55732.1; JOINED; Genomic_DNA.
DR   EMBL; AF283829; AAL55732.1; JOINED; Genomic_DNA.
DR   EMBL; BC000479; AAH00479.1; -; mRNA.
DR   EMBL; BC084538; AAH84538.1; -; mRNA.
DR   EMBL; X61037; CAA43372.1; -; mRNA.
DR   IPI; IPI00012866; -.
DR   PIR; A39360; A39360.
DR   RefSeq; NP_001014431.1; -.
DR   RefSeq; NP_001014432.1; -.
DR   RefSeq; NP_005154.2; -.
DR   UniGene; Hs.525622; -.
DR   PDB; 1H10; X-ray; 1.40 A; A=1-123.
DR   PDB; 1UNP; X-ray; 1.65 A; A=1-121.
DR   PDB; 1UNQ; X-ray; 0.98 A; A=1-123.
DR   PDB; 1UNR; X-ray; 1.25 A; A=1-123.
DR   PDB; 2UVM; X-ray; 1.94 A; A=1-123.
DR   PDB; 2UZR; X-ray; 1.94 A; A=1-123.
DR   PDB; 2UZS; X-ray; 2.46 A; A=1-123.
DR   PDB; 3CQU; X-ray; 2.20 A; A=144-480.
DR   PDB; 3CQW; X-ray; 2.00 A; A=144-480.
DR   PDBsum; 1H10; -.
DR   PDBsum; 1UNP; -.
DR   PDBsum; 1UNQ; -.
DR   PDBsum; 1UNR; -.
DR   PDBsum; 2UVM; -.
DR   PDBsum; 2UZR; -.
DR   PDBsum; 2UZS; -.
DR   PDBsum; 3CQU; -.
DR   PDBsum; 3CQW; -.
DR   ProteinModelPortal; P31749; -.
DR   DIP; DIP-24269N; -.
DR   IntAct; P31749; 38.
DR   MINT; MINT-203775; -.
DR   STRING; P31749; -.
DR   PhosphoSite; P31749; -.
DR   PRIDE; P31749; -.
DR   Ensembl; ENST00000349310; ENSP00000270202; ENSG00000142208.
DR   Ensembl; ENST00000402615; ENSP00000385326; ENSG00000142208.
DR   Ensembl; ENST00000407796; ENSP00000384293; ENSG00000142208.
DR   GeneID; 207; -.
DR   KEGG; hsa:207; -.
DR   UCSC; uc001ypk.1; human.
DR   CTD; 207; -.
DR   GeneCards; GC14M105235; -.
DR   H-InvDB; HIX0012019; -.
DR   HGNC; HGNC:391; AKT1.
DR   HPA; CAB003765; -.
DR   HPA; HPA002891; -.
DR   MIM; 114480; phenotype.
DR   MIM; 114500; phenotype.
DR   MIM; 164730; gene.
DR   MIM; 604370; phenotype.
DR   PharmGKB; PA24684; -.
DR   eggNOG; prNOG10074; -.
DR   HOGENOM; HBG755340; -.
DR   HOVERGEN; HBG108317; -.
DR   InParanoid; P31749; -.
DR   OMA; RFFASIV; -.
DR   OrthoDB; EOG97H886; -.
DR   PhylomeDB; P31749; -.
DR   BRENDA; 2.7.11.1; 247.
DR   Pathway_Interaction_DB; a6b1_a6b4_integrin_pathway; a6b1 and a6b4 Integrin signaling.
DR   Pathway_Interaction_DB; amb2_neutrophils_pathway; amb2 Integrin signaling.
DR   Pathway_Interaction_DB; angiopoietinreceptor_pathway; Angiopoietin receptor Tie2-mediated signaling.
DR   Pathway_Interaction_DB; aurora_a_pathway; Aurora A signaling.
DR   Pathway_Interaction_DB; bcr_5pathway; BCR signaling pathway.
DR   Pathway_Interaction_DB; ceramidepathway; Ceramide signaling pathway.
DR   Pathway_Interaction_DB; pi3kciaktpathway; Class I PI3K signaling events mediated by Akt.
DR   Pathway_Interaction_DB; ar_pathway; Coregulation of Androgen receptor activity.
DR   Pathway_Interaction_DB; endothelinpathway; Endothelins.
DR   Pathway_Interaction_DB; fcer1pathway; Fc-epsilon receptor I signaling in mast cells.
DR   Pathway_Interaction_DB; fgf_pathway; FGF signaling pathway.
DR   Pathway_Interaction_DB; hnf3bpathway; FOXA2 and FOXA3 transcription factor networks.
DR   Pathway_Interaction_DB; foxopathway; FoxO family signaling.
DR   Pathway_Interaction_DB; hedgehog_glipathway; Hedgehog signaling events mediated by Gli proteins.
DR   Pathway_Interaction_DB; hif1_tfpathway; HIF-1-alpha transcription factor network.
DR   Pathway_Interaction_DB; ifngpathway; IFN-gamma pathway.
DR   Pathway_Interaction_DB; igf1_pathway; IGF1 pathway.
DR   Pathway_Interaction_DB; il2_pi3kpathway; IL2 signaling events mediated by PI3K.
DR   Pathway_Interaction_DB; il4_2pathway; IL4-mediated signaling events.
DR   Pathway_Interaction_DB; il6_7pathway; IL6-mediated signaling events.
DR   Pathway_Interaction_DB; insulin_pathway; Insulin Pathway.
DR   Pathway_Interaction_DB; insulin_glucose_pathway; Insulin-mediated glucose transport.
DR   Pathway_Interaction_DB; avb3_integrin_pathway; Integrins in angiogenesis.
DR   Pathway_Interaction_DB; lysophospholipid_pathway; LPA receptor mediated events.
DR   Pathway_Interaction_DB; mtor_4pathway; mTOR signaling pathway.
DR   Pathway_Interaction_DB; p75ntrpathway; p75(NTR)-mediated signaling.
DR   Pathway_Interaction_DB; pdgfrbpathway; PDGFR-beta signaling pathway.
DR   Pathway_Interaction_DB; er_nongenomic_pathway; Plasma membrane estrogen receptor signaling.
DR   Pathway_Interaction_DB; reelinpathway; Reelin signaling pathway.
DR   Pathway_Interaction_DB; smad2_3nuclearpathway; Regulation of nuclear SMAD2/3 signaling.
DR   Pathway_Interaction_DB; telomerasepathway; Regulation of Telomerase.
DR   Pathway_Interaction_DB; retinoic_acid_pathway; Retinoic acid receptors-mediated signaling.
DR   Pathway_Interaction_DB; s1p_s1p3_pathway; S1P3 pathway.
DR   Pathway_Interaction_DB; met_pathway; Signaling events activated by Hepatocyte Growth Factor Receptor (c-Met).
DR   Pathway_Interaction_DB; ptp1bpathway; Signaling events mediated by PTP1B.
DR   Pathway_Interaction_DB; kitpathway; Signaling events mediated by Stem cell factor receptor (c-Kit).
DR   Pathway_Interaction_DB; hedgehog_2pathway; Signaling events mediated by the Hedgehog family.
DR   Pathway_Interaction_DB; vegfr1_2_pathway; Signaling events mediated by VEGFR1 and VEGFR2.
DR   Pathway_Interaction_DB; tcrpathway; TCR signaling in naive CD4+ T cells.
DR   Pathway_Interaction_DB; cd8tcrpathway; TCR signaling in naive CD8+ T cells.
DR   Pathway_Interaction_DB; txa2pathway; Thromboxane A2 receptor signaling.
DR   Pathway_Interaction_DB; pi3kplctrkpathway; Trk receptor signaling mediated by PI3K and PLC-gamma.
DR   Pathway_Interaction_DB; vegfr1_pathway; VEGFR1 specific signals.
DR   Pathway_Interaction_DB; lymphangiogenesis_pathway; VEGFR3 signaling in lymphatic endothelium.
DR   Reactome; REACT_11061; Signalling by NGF.
DR   Reactome; REACT_12508; Metabolism of nitric oxide.
DR   Reactome; REACT_13698; Regulation of beta-cell development.
DR   Reactome; REACT_14797; Signaling by GPCR.
DR   Reactome; REACT_578; Apoptosis.
DR   Reactome; REACT_604; Hemostasis.
DR   Reactome; REACT_6900; Signaling in Immune system.
DR   BindingDB; P31749; -.
DR   DrugBank; DB00171; Adenosine triphosphate.
DR   DrugBank; DB01169; Arsenic trioxide.
DR   NextBio; 828; -.
DR   PMAP-CutDB; P31749; -.
DR   ArrayExpress; P31749; -.
DR   Bgee; P31749; -.
DR   CleanEx; HS_AKT1; -.
DR   Genevestigator; P31749; -.
DR   GermOnline; ENSG00000142208; Homo sapiens.
DR   GO; GO:0005829; C:cytosol; EXP:Reactome.
DR   GO; GO:0005654; C:nucleoplasm; EXP:Reactome.
DR   GO; GO:0005886; C:plasma membrane; IDA:UniProtKB.
DR   GO; GO:0005524; F:ATP binding; IC:UniProtKB.
DR   GO; GO:0019899; F:enzyme binding; ISS:BHF-UCL.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0030235; F:nitric-oxide synthase regulator activity; IMP:BHF-UCL.
DR   GO; GO:0005547; F:phosphatidylinositol-3,4,5-trisphosphate bi...; IDA:UniProtKB.
DR   GO; GO:0043325; F:phosphatidylinositol-3,4-bisphosphate binding; IDA:UniProtKB.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB.
DR   GO; GO:0008633; P:activation of pro-apoptotic gene products; EXP:Reactome.
DR   GO; GO:0006924; P:activation-induced cell death of T cells; IMP:MGI.
DR   GO; GO:0007186; P:G-protein coupled receptor protein signalin...; TAS:ProtInc.
DR   GO; GO:0005978; P:glycogen biosynthetic process; IEA:UniProtKB-KW.
DR   GO; GO:0008286; P:insulin receptor signaling pathway; IMP:UniProtKB.
DR   GO; GO:0048009; P:insulin-like growth factor receptor signali...; IMP:UniProtKB.
DR   GO; GO:0031999; P:negative regulation of fatty acid beta-oxid...; IMP:BHF-UCL.
DR   GO; GO:0010748; P:negative regulation of plasma membrane long...; IMP:BHF-UCL.
DR   GO; GO:0006469; P:negative regulation of protein kinase activity; IMP:BHF-UCL.
DR   GO; GO:0006809; P:nitric oxide biosynthetic process; TAS:ProtInc.
DR   GO; GO:0018105; P:peptidyl-serine phosphorylation; IDA:UniProtKB.
DR   GO; GO:0030307; P:positive regulation of cell growth; IDA:UniProtKB.
DR   GO; GO:0031659; P:positive regulation of cyclin-dependent pro...; IDA:BHF-UCL.
DR   GO; GO:0090004; P:positive regulation of establishment of pro...; IMP:BHF-UCL.
DR   GO; GO:0045600; P:positive regulation of fat cell differentia...; IMP:BHF-UCL.
DR   GO; GO:0046326; P:positive regulation of glucose import; IMP:BHF-UCL.
DR   GO; GO:0045725; P:positive regulation of glycogen biosyntheti...; IMP:BHF-UCL.
DR   GO; GO:0046889; P:positive regulation of lipid biosynthetic p...; IMP:BHF-UCL.
DR   GO; GO:0045429; P:positive regulation of nitric oxide biosynt...; IMP:BHF-UCL.
DR   GO; GO:0051000; P:positive regulation of nitric-oxide synthas...; IMP:BHF-UCL.
DR   GO; GO:0046777; P:protein amino acid autophosphorylation; TAS:UniProtKB.
DR   GO; GO:0000060; P:protein import into nucleus, translocation; IMP:UniProtKB.
DR   GO; GO:0010975; P:regulation of neuron projection development; ISS:UniProtKB.
DR   GO; GO:0006417; P:regulation of translation; IEA:UniProtKB-KW.
DR   GO; GO:0034405; P:response to fluid shear stress; IMP:BHF-UCL.
DR   GO; GO:0009408; P:response to heat; TAS:ProtInc.
DR   GO; GO:0070141; P:response to UV-A; IDA:BHF-UCL.
DR   InterPro; IPR000961; AGC-kinase_C.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR011993; PH_type.
DR   InterPro; IPR017892; Pkinase_C.
DR   InterPro; IPR001849; Pleckstrin_homology.
DR   InterPro; IPR000719; Prot_kinase_cat_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR017442; Se/Thr_prot_kinase-like_dom.
DR   InterPro; IPR008271; Ser/Thr_prot_kinase_AS.
DR   InterPro; IPR002290; Ser/Thr_prot_kinase_dom.
DR   InterPro; IPR015744; Serine/threonine_Kinase_Rac.
DR   Gene3D; G3DSA:2.30.29.30; PH_type; 1.
DR   PANTHER; PTHR22985:SF69; Akt; 1.
DR   Pfam; PF00169; PH; 1.
DR   Pfam; PF00069; Pkinase; 1.
DR   Pfam; PF00433; Pkinase_C; 1.
DR   SMART; SM00233; PH; 1.
DR   SMART; SM00133; S_TK_X; 1.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF56112; Kinase_like; 1.
DR   PROSITE; PS51285; AGC_KINASE_CTER; 1.
DR   PROSITE; PS50003; PH_DOMAIN; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Apoptosis; ATP-binding; Carbohydrate metabolism;
KW   Cell membrane; Complete proteome; Cytoplasm; Disease mutation;
KW   Glucose metabolism; Glycogen biosynthesis; Glycogen metabolism;
KW   Kinase; Membrane; Neurogenesis; Nucleotide-binding; Nucleus;
KW   Phosphoprotein; Polymorphism; Proto-oncogene;
KW   Serine/threonine-protein kinase; Sugar transport; Transferase;
KW   Translation regulation; Transport; Ubl conjugation.
FT   CHAIN         1    480       RAC-alpha serine/threonine-protein
FT                                kinase.
FT                                /FTId=PRO_0000085605.
FT   DOMAIN        5    108       PH.
FT   DOMAIN      150    408       Protein kinase.
FT   DOMAIN      409    480       AGC-kinase C-terminal.
FT   NP_BIND     156    164       ATP (By similarity).
FT   ACT_SITE    274    274       Proton acceptor (By similarity).
FT   BINDING     179    179       ATP (By similarity).
FT   MOD_RES     124    124       Phosphoserine.
FT   MOD_RES     126    126       Phosphoserine.
FT   MOD_RES     129    129       Phosphoserine.
FT   MOD_RES     308    308       Phosphothreonine; by PDPK1.
FT   MOD_RES     473    473       Phosphoserine.
FT   MOD_RES     474    474       Phosphotyrosine.
FT   VARIANT      17     17       E -> K (in breast cancer, colorectal
FT                                cancer and ovarian cancer; somatic
FT                                mutation; alters the PH domain
FT                                conformation; results in activation of
FT                                the protein; alters the subcellular
FT                                location of the protein to the plasma
FT                                membrane).
FT                                /FTId=VAR_055422.
FT   VARIANT     167    167       V -> A (in dbSNP:rs11555433).
FT                                /FTId=VAR_051617.
FT   MUTAGEN       8      8       K->R: Substantial reduction of
FT                                ubiquitination, phosphorylation at T-308
FT                                and S-473, AKT activation as well as
FT                                IGF1-induced membrane recruitment.
FT                                Decrease in ubiquitination and
FT                                phosphorylation at T-308 as well as
FT                                impaired association with the membrane;
FT                                when associated with K-17.
FT   MUTAGEN      14     14       K->R: Substantial reduction of
FT                                ubiquitination, phosphorylation at T-308
FT                                and S-473, AKT activation, loss of
FT                                binding to PIP3 as well as IGF1-induced
FT                                membrane recruitment.
FT   MUTAGEN      17     17       E->K: Increase in basal ubiquitination,
FT                                phosphorylation at T-308 and important
FT                                increase in membrane recruitment.
FT                                Decrease in ubiquitination,
FT                                phosphorylation at T-308 as well as
FT                                impaired association with the membrane;
FT                                when associated with R-8.
FT   MUTAGEN     308    308       T->D: 5-fold activation and 18-fold
FT                                activation; when associated with D-473.
FT   MUTAGEN     473    473       S->D: 7-fold activation and 25-fold
FT                                activation; when associated with D-308.
FT   MUTAGEN     474    474       Y->F: 55% inhibition of activation.
FT   CONFLICT    173    174       GR -> A (in Ref. 4; CAA43372).
FT   CONFLICT    202    202       L -> Q (in Ref. 4; CAA43372).
FT   CONFLICT    212    212       A -> R (in Ref. 4; CAA43372).
FT   CONFLICT    246    246       S -> A (in Ref. 4; CAA43372).
FT   CONFLICT    409    409       A -> T (in Ref. 4; CAA43372).
FT   CONFLICT    476    476       A -> P (in Ref. 4; CAA43372).
FT   CONFLICT    478    478       G -> A (in Ref. 4; CAA43372).
FT   CONFLICT    478    478       G -> S (in Ref. 1; AAA36539 and 2;
FT                                AAL55732).
FT   STRAND        6     15
FT   STRAND       17     19
FT   STRAND       22     30
FT   STRAND       33     40
FT   STRAND       52     56
FT   STRAND       61     65
FT   STRAND       67     79
FT   STRAND       82     89
FT   HELIX        93    118
FT   HELIX       147    149
FT   STRAND      150    159
FT   STRAND      162    169
FT   TURN        170    172
FT   STRAND      175    182
FT   HELIX       183    188
FT   HELIX       192    204
FT   STRAND      213    218
FT   STRAND      220    228
FT   HELIX       235    242
FT   HELIX       247    266
FT   HELIX       277    279
FT   STRAND      280    282
FT   STRAND      288    290
FT   HELIX       313    315
FT   HELIX       318    321
FT   HELIX       329    344
FT   HELIX       354    363
FT   HELIX       374    383
FT   HELIX       388    390
FT   TURN        396    398
FT   HELIX       399    403
FT   HELIX       406    408
FT   HELIX       413    418
FT   HELIX       440    443
SQ   SEQUENCE   480 AA;  55686 MW;  6EAFF4F8AD436714 CRC64;
     MSDVAIVKEG WLHKRGEYIK TWRPRYFLLK NDGTFIGYKE RPQDVDQREA PLNNFSVAQC
     QLMKTERPRP NTFIIRCLQW TTVIERTFHV ETPEEREEWT TAIQTVADGL KKQEEEEMDF
     RSGSPSDNSG AEEMEVSLAK PKHRVTMNEF EYLKLLGKGT FGKVILVKEK ATGRYYAMKI
     LKKEVIVAKD EVAHTLTENR VLQNSRHPFL TALKYSFQTH DRLCFVMEYA NGGELFFHLS
     RERVFSEDRA RFYGAEIVSA LDYLHSEKNV VYRDLKLENL MLDKDGHIKI TDFGLCKEGI
     KDGATMKTFC GTPEYLAPEV LEDNDYGRAV DWWGLGVVMY EMMCGRLPFY NQDHEKLFEL
     ILMEEIRFPR TLGPEAKSLL SGLLKKDPKQ RLGGGSEDAK EIMQHRFFAG IVWQHVYEKK
     LSPPFKPQVT SETDTRYFDE EFTAQMITIT PPDQDDSMEC VDSERRPHFP QFSYSASGTA
//
